GC Cell Appoints Kang Jin-hee as New Chief Development Officer

GC Cell, a contract development and manufacturing organization (CDMO) company specializing in cell and gene therapy, announced on the 4th that it has newly appointed Jinhee Kang, head of the development division and an expert in clinical development and global regulations, as Chief Development Officer (CDO) to strengthen its research and development (R&D) capabilities.

Jang Jin-hee, Chief Development Officer (CDO) of GC Cell [Photo by GC Cell]

Newly appointed CDO Kang previously served as Head of Global Strategy and Chief Regulatory Officer (CRO) at NeoImmuneTech, where she contributed to the development of new pipelines for T-cell-based immuno-oncology and infectious disease therapies, as well as the establishment of approval strategies for the US and European markets. She has accumulated extensive experience and expertise in the global biopharmaceutical market, including business planning and management. Kang also gained diverse experience as a global clinical and regulatory expert at Polus, Celltrion, ELC Group (now Product Life Group), and Otsuka Pharmaceutical.

GC Cell aims to establish a higher level of R&D strategy and global expansion strategy through new leadership and expertise by combining the recent recruitment of Sungyong Won, head of the cell therapy research institute, with the addition of Jinhee Kang as head of the development division.

A GC Cell official stated, “Based on Jinhee Kang’s extensive experience and expertise in global pharmaceutical and bio companies, we expect her to significantly contribute to solidifying our cell and gene therapy development platform strategy and showcasing the company’s technological capabilities and pipeline in the global market.”